Teva, MedinCell win FDA approval for slow-release schizophrenia drug Uzedy


Teva Pharmaceuticals and MedinCell have recently achieved a significant milestone in the field of mental health with the FDA approval of their slow-release schizophrenia drug, Uzedy. This groundbreaking medication offers new hope for patients living with schizophrenia by providing a long-acting treatment option. In this blog post, we will explore the key points surrounding Teva and MedinCell’s FDA approval of Uzedy and its potential impact on the management of schizophrenia.

Key Points:

  1. Understanding schizophrenia:
    Schizophrenia is a chronic mental health disorder characterized by abnormal thoughts, perceptions, and behaviors. It affects millions of people worldwide and impairs daily functioning and quality of life. The treatment of schizophrenia typically involves a combination of medications, therapy, and support. However, adherence to medication can be challenging, making the development of a slow-release option like Uzedy an important breakthrough.
  2. The Development of Uzedy:
    Teva Pharmaceuticals and MedinCell collaborated in the development of Uzedy, a slow-release formulation that addresses the limitations of traditional oral medications for schizophrenia. Uzedy utilizes MedinCell’s proprietary BEPO technology, which allows for controlled and consistent release of the active ingredient over an extended period. This innovative approach offers potential advantages such as reduced dosing frequency and improved medication adherence.
  3. Significance of FDA Approval:
    The FDA approval of Uzedy represents a crucial milestone in the treatment of schizophrenia. It signifies that the medication has met rigorous safety and efficacy standards, allowing it to be prescribed to patients in the United States. This approval provides healthcare professionals and patients with a new treatment option that may enhance symptom management and overall disease control.
  4. Benefits of Slow-Release Medications:
    Slow-release medications, like Uzedy, offer several benefits for patients with schizophrenia. The controlled release of the active ingredient in these formulations provides consistent blood levels, reducing the fluctuations often experienced with immediate-release medications. Moreover, the decreased dosing frequency can simplify the medication regimen and improve adherence, which is crucial for managing symptoms and preventing relapses.
  5. Potential Impact on Schizophrenia Management:
    The FDA approval of Uzedy has the potential to revolutionize the management of schizophrenia. By offering a long-acting treatment option, Uzedy addresses one of the key challenges in the treatment journey – medication adherence. Improved adherence can lead to better symptom control, reduction in hospitalizations, and enhanced overall outcomes for individuals living with schizophrenia.


Teva Pharmaceuticals and MedinCell’s success in obtaining FDA approval for Uzedy marks a significant advancement in the field of schizophrenia treatment. The slow-release formulation of this medication tackles the issue of medication adherence, a common barrier in managing the symptoms of schizophrenia. The potential benefits of Uzedy, including consistent blood levels and reduced dosing frequency, offer new possibilities for improved disease control and overall quality of life for patients. As Uzedy becomes available to patients in the United States, it brings hope for a brighter future in the management of schizophrenia paving the way for further innovation in mental health treatment.